Vitamin D3: clinical trials recruiting now
7
Recruiting trials
15
Conditions studied
3
US states with sites
5
Countries
FDA drug label
- FDA-approved
- Yes. Vitamin D3 appears in the FDA drug-label database. Marketed as Folixate.
FDA-approved use
Folixate ™ is indicated for dietary management of patients with unique nutritional needs requiring increased folate level and Vitamin D supplementation. Folixate™ can be taken by women of childbearing age, pregnant women, and lactating and nonlactating mothers.
Phase breakdown
Early Phase 1 1
Phase 2 1
Not applicable 5
Conditions being studied
Recruiting trials involving Vitamin D3
- Effect of Vitamin D3 Supplementation on Brain Waves in Male Epileptic Patients With Hypovitaminosis D
- Effects of Vitamin D3 and Yeast Beta-Glucan Supplementation on Glycemic Control and Cardiovascular Disease Risk in Patients With Type 2 Diabetes
- High Dose Interval Vitamin D Supplementation in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy
- Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients
- Oral Vitamin D3 Effect on Inflammatory Biomarkers in Ulcerative Colitis Patients
- Triamcinolone With Vitamin D Synergistic Efficacy in Psoriasis
- Vitamin D3 Supplementation Regimens and Preeclampsia Risk
Common questions
Is Vitamin D3 FDA-approved?
Yes, marketed as Folixate.
How many recruiting trials involve Vitamin D3?
7 recruiting trials across 15 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.